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ABSTRACT
Sjo¨gren’s syndrome (SS) is a chronic and pro-
gressive multisystem autoimmune disease typi-
cally managed by rheumatologists. Diagnostic
delays are common, due in large part to the
non-specific and variable nature of SS symptoms
and the slow progression of disease. The hallmark
characteristics of SS are dry eye and dry mouth,
but there are a broad range of other possible
symptoms such as joint and muscle pain, skin
rashes, chronic dry cough, vaginal dryness,
extremity numbness or tingling, and disabling
fatigue. Given that dry eye and dry mouth are
typically the earliest presenting complaints, eye
care clinicians and dental professionals are often
the first point of medical contact and can provide
critical collaboration with rheumatologists to
facilitate both timely diagnosis and ongoing care
of patients with SS. Current diagnostic criteria
advocated by the American College of Rheuma-
tology are predicated on the presence of signs/
symptoms suggestive of SS along with at least two
objective factors such as traditional biomarker
positivity, salivary gland biopsy findings, and/or
presence of keratoconjunctivitis sicca. Tradi-
tional biomarkers for SS include the autoanti-
bodies anti-Sjo¨gren’s syndrome-related antigen A
(SS-A/Ro), anti-Sjo¨gren’s syndrome-related anti-
gen B (SS-B/La), antinuclear antibody (ANA)
titers, and rheumatoid factor (RF). While diag-
nostically useful, these biomarkers have low
specificity for SS and are not always positive,
especially in early cases of SS. Several
newly-identified biomarkers for SS include
autoantibodies to proteins specific to the salivary
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
0F87F060569E0A33.
K. A. Beckman (&)




Ohio State University, Columbus, OH, USA
J. Luchs
Hofstra University School of Medicine, Hempstead,
NY, USA
J. Luchs
South Shore Eye Care, Wantagh, NY, USA
M. S. Milner
The Eye Center of Southern Connecticut, PC,
Hamden, CT, USA
M. S. Milner
Yale University School of Medicine, New Haven, CT,
USA
J. L. Ambrus Jr.
Division of Allergy, Immunology and
Rheumatology, Department of Medicine, SUNY at
Buffalo School of Medicine, Buffalo, NY, USA
Adv Ther (2017) 34:799–812
DOI 10.1007/s12325-017-0501-3
and lacrimal glands [SP-1 (salivary gland pro-
tein-1), PSP (parotid secretory protein), CA-6
(carbonic anhydrase VI)]. Data suggest that these
novel biomarkers may appear earlier in the course
ofdiseaseandareoften identified incases that test
negative to traditional biomarkers. The Sjo¨ test
is a commercially available diagnostic panel that
incorporates testing for traditional SS biomarkers
(anti-SS-A/Ro, anti-SS-B/La, ANA, and RF), as well
as three novel, proprietary early biomarkers (an-
tibodies to SP-1, PSP, and CA-6) which provide
greater sensitivity and specificity than traditional
biomarker testing alone. Timely diagnosis of SS
requires appropriate clinical vigilance for poten-
tial SS symptoms, referral and collaborative
communication among rheumatology, ophthal-
mology, and oral care professions, and proactive
differential work-up that includes both physical
and laboratory evaluations.
Keywords: Autoantibodies; Diagnosis;
Keratoconjunctivitis sicca; Novel biomarkers;
Salivary gland biopsy; Sjo¨gren’s syndrome; Sjo¨
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INTRODUCTION
Sjo¨gren’s syndrome (SS) is a chronic, progres-
sive, multisystem autoimmune disease that
involves primarily the lacrimal and salivary
glands [1, 2]. The disease may also have wide-
spread systemic manifestations, generally
appearing years after the initial ocular and oral
symptoms, and which can have major adverse
effects on patient quality of life and survival.
Lacrimal gland dysfunction produces dry eye
symptomatology which is a non-specific, yet
hallmark, feature of SS. A large study of 327
patients presenting with clinically significant
aqueous-deficient dry eye (ADDE) in the US
found 11.6% of the patients to have SS [3].
Salivary gland dysfunction leads to dry mouth
and associated problems such as trouble swal-
lowing dry food, dental caries, and even oral
candidiasis [2].
Because of the ambiguous nature and grad-
ual onset of SS symptoms, patients may seek
medical attention from a variety of clinical
specialists. While SS is a disease typically over-
seen by rheumatologists, ophthalmologists, and
oral medicine clinicians are often the first point
of patient contact when early symptoms appear.
Awareness of SS is important to facilitate diag-
nostic suspicion and trigger consultation with
other professionals as needed. Following a
review of the clinical features of SS and diag-
nostic considerations and challenges, this arti-
cle will provide an overview of the Sjo¨ test, a
non-invasive approach to diagnosis which
incorporates some novel biomarkers for SS and
may be a useful adjunctive tool for differential
workup.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Epidemiology of SS
SS is the second most common autoimmune
rheumatic disease [2], with a prevalence of
approximately 1% (range 0.1–4.8%) [2, 4] and
an incidence of about 7 per 100,000 per-
son–years at risk [5, 6]. In total, up to 4 million
Americans have SS [7–9].
When diagnosed in an otherwise healthy
individual, SS is classified as primary SS. Primary
SS typically presents with ADDE syndrome, dry
mouth symptoms, evidence of reduced salivary
secretion, and may show positivity for various
autoantibodies [10]. About half of SS cases are
the primary type [3, 9]. SS also manifests in
patients with a coexisting autoimmune disease
such as rheumatoid arthritis (RA) [10]. These
distinctions have no bearing on the clinical
management of SS.
Women constitute the vast majority of SS
patients, with a female to male ratio in inci-
dence of approximately 9:1 [6]. Onset typically
occurs during the 4th or 5th decade of life, but
SS may occur at any age [11]. The overall age of
primary SS patients at diagnosis has been
reported to be 56 years (95% CI 53–60 years) [5].
Among women, the incidence of primary SS
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increases with age and peaks during the years of
55–65. In contrast, among men, primary SS is
most common among individuals 65 years or
older [5].
Clinical Manifestations of SS
The cardinal complaints of SS are dry eyes
(xerophthalmia) and dry mouth (xerostomia)
[7, 12]. The dry eye symptoms of SS may
include a variety of sensations, including
itching, grittiness, and soreness with a normal
appearing eye [4, 7]. Other ocular symptoms
are complaints of eye fatigue, reduced visual
acuity, photosensitivity, ocular discharge,
erythema, and the sensation of a film across
the visual field [7]. Patients who previously
wore contact lenses may report that they
cannot continue to wear them and need to
use tear substitutes [4]. Patients may also
report accumulation of sticky mucus over-
night that makes opening their eyes difficult
in the morning [4]. The patient’s ocular
symptoms may be aggravated by various
external factors, such as low humidity levels
and exposure to cigarette smoke, as well as
anticholinergic drugs [7].
On examination, patients with SS can exhi-
bit a variety of ocular findings [4, 7]. These
include accumulation of mucus secretions
along the inner canthus and decreased tear
secretion, although there is no correlation
between tear flow rates and ocular discomfort.
Desiccation may cause superficial/shallow ero-
sions of the corneal epithelium, and filamentary
keratitis, which can be seen on slit lamp exam-
ination, may occur in more severe cases. In
some patients, conjunctivitis may occur due to
Staphylococcus aureus infection. Rare ocular
manifestations include lacrimal gland enlarge-
ment and other complications, such as corneal
ulceration, vascularization, opacification, and,
very rarely, perforation.
Dry mouth, the other hallmark symptom of
SS, is associated with an inability to swallow dry
food without liquid, dried and fissured tongue,
cheilitis, aphthae, chronic oral candidiasis, and
dental caries [4, 13]. Involvement of other
exocrine glands may produce complaints of dry
skin and hair, vaginal dryness, and gastroin-
testinal symptoms due to impaired secretion of
protective mucus [4].
SS is a systemic disease with a range of sys-
temic symptoms such as fatigue and arthralgia,
along with a number of more serious compli-
cations (Table 1). Data from the Sjo¨gren’s
International Collaborative Clinical Alliance
(SICCA) registry suggest that primary SS is
characterized by immunologic and hematologic
abnormalities that may affect multiple organ
systems [14]. Patients with SS have an increased
risk of cerebrovascular events and myocardial
infarction [15], and are more than twice as
likely as age- and sex-matched controls to have
hypertension and hypertriglyceridemia. Other
systemic developments include arthritis (often
misdiagnosed as RA), interstitial cystitis, neu-
ropathy, and vasculopathies, including
anti-phospholipid antibody syndrome. Renal
involvement is rare, occurring in less than 10%
of cases [16] and most commonly involving
renal tubular acidosis. Autonomic symptoms
may affect 50% of individuals with SS [17].
Clinical pulmonary involvement occurs in
20–30% of patients with SS and is associated
with a four-fold increase in 10-year mortality
[18]. A standardized tool for measuring SS dis-
ease activity, the European League Against
Rheumatism (EULAR) Sjo¨gren’s syndrome dis-
ease activity index or ESSDAI [19], was intro-
duced in 2010 and is increasingly used in
clinical practice and clinical trials.
The risk of lymphoma in individuals with SS
has been estimated to be 16–37.5 times higher
than that in the general population [20, 21]. A
meta-analysis of 14 primary SS studies found an
increased risk of non-Hodgkin lymphoma
(pooled RR 13.76; 95% CI 8.53–18.99) and
thyroid cancer (pooled RR 2.58, 95% CI
1.14–4.03) [22].
Due to the range of medical complications
associated with SS, it is not surprising that the
disease is associated with significant impair-
ments in quality of life [23–27] and functioning
[25, 28]. Patients with SS also have a high rate of
depression [26]. These factors result in a high
burden of illness and high health care costs for
patients with SS [29].
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DIAGNOSTIC ASPECTS
AND CHALLENGES
One of the major challenges of SS is that it can
be difficult to diagnose. Data show that patients
have symptoms for an average of 3.9 years
before being diagnosed with SS [9], and it has
been estimated that more than half of adults
with SS are undiagnosed [7, 10, 30]. There are
many factors that add to the difficulty of diag-
nosing SS, including variable expression of
ocular and non-ocular symptoms, symptoms
that do not always present at the same time,
and slow disease progression [7, 10, 31, 32].
On average, systemic and/or extraglandular
ocular complications develop about 10 years
after the initial onset of dry eye symptoms in
patients with SS [33], underscoring the diag-
nostic importance of dry eye symptoms as an
early manifestation of the disease, especially if
dry mouth symptoms are also present. Early
diagnosis and treatment of SS can be an
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important step to help prevent or decrease the
complications of SS, facilitate early treatment of
existing complications, and identify patients at
risk for systemic complications of SS for which
monitoring is needed [10, 15, 26, 31, 33, 34].
Delayed diagnosis can also lead to psychological
distress associated with unexplained symptoms
[26].
Because of the systemic nature of SS and the
non-specific symptomatology of the disease, a
multidisciplinary team approach with input
from relevant specialists is often needed to both
diagnose SS and manage the variety of possible
manifestations of the disease.
Diagnostic Workup
Historically, there have been a number of pub-
lished diagnostic guidelines for SS, mainly for
the purpose of standardizing inclusion criteria
for clinical trials, but there has been a
notable lack of universal acceptance of any one
set of guidelines. The American European Con-
sensus Group (AECG) criteria, published in
2002, was considered the first ‘‘gold standard’’
for Sjo¨gren’s diagnosis and combined subjective
findings of dry eye and dry mouth complaints
with objective test results such as dry eye test,
minor salivary gland biopsy, salivary gland
tests, and traditional biomarker positivity
[(anti-Sjo¨gren’s syndrome-related antigen A
(SS-A/Ro) and/or anti-Sjo¨gren’s syndrome-re-
lated antigen B (SS-B/La) positivity] [35]. Pres-
ence of at least three of the four objective
criteria confirms diagnosis. Diagnostic thresh-
old was achieved by the presence of at least four
of the six items, as long as one of the items was
either positive biopsy histopathology or bio-
marker positivity. In 2012, a new set of criteria
based on the National Institutes of Health--
funded Sjo¨gren’s International Collaborative
Clinical Alliance (SICCA) registry were pub-
lished upon receiving provisional approval by
the American College of Rheumatology (ACR)
[36]. These criteria are to be applied to patients
with signs/symptoms suggestive of SS, with
diagnosis being determined by meeting at least
2 of the following three standardized, objective
measures: traditional biomarker positivity
(anti-SS-A/Ro and/or anti-SS-B/La) or positive
rheumatoid factor (RF) and antinuclear antigen
(ANA) titer C1:320; relevant labial salivary
gland biopsy findings; and/or presence of kera-
toconjunctivitis sicca (KCS) (Table 2). In a
comparison of these two sets of guidelines in
646 individuals with sicca symptoms, a total of
303 participants were classified as having SS by
either AECG criteria (n = 279) or 2012 ACR cri-
teria (n = 268); 244 of the 303 (81%) diagnosed
cases fulfilled both the AECG and ACR criteria,
implying good, but not complete, concordant
diagnostic results [37].
Most recently, an international multispe-
cialty panel of experts has produced a new
classification criteria for SS which combines
features of the ACR and European League
Against Rheumatism (EULAR) guidelines [38].
As in the ACR guidelines, dry eye/dry mouth
symptoms alone are not sufficient for SS diag-
nosis, but are used to identify patients who are
candidates for objective workup. Classification
is based on the weighted sum of five objective
Table 2 Proposed classiﬁcation criteria for Sjo¨gren’s syndrome (American College of Rheumatology 2012); adapted with
permission from Shiboski et al. [36]
The classiﬁcation of Sjo¨gren’s syndrome, which applies to individuals with signs/symptoms that may be suggestive of SS,
will be met in patients who have at least two of the following three objective features:
1. Positive serum anti-SS-A/Ro and/or anti-SS-B/La or (positive rheumatoid factor and ANA C1:320)
2. Labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a focus score C1 focus/4 mm2
3. Keratoconjunctivitis sicca with ocular staining score C3 (assuming that individual is not currently using daily eye drops
for glaucoma, and has not had corneal surgery or cosmetic eyelid surgery in the last 5 years)
SS Sjo¨gren’s syndrome, ANA antinuclear antibody
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assessments with a total score C4 considered
diagnostic for SS. In these new guidelines, two
measures, focal lymphocytic sialadenitis and
anti-SS-A/Ro positivity, are given the highest
score of ‘‘3’’; three other items are weighted with
a score of ‘‘1’’: Ocular Staining Score C5 (or van
Bijsterveld score C4) in at least 1 eye; Schirmer’s
test B5 mm/5 min in at least 1 eye, and
unstimulated whole saliva flow rate B0.1 mL/
min. Other traditional biomarkers (anti-SS-B/La,
ANA, RF) are not included. The expert panel
decided to exclude positive serology for
anti-SS-B/La from these new guidelines in light
of evidence that it appears to have no inde-
pendent diagnostic significance.
In the workup of a patient with suspected SS,
the aim is to rule out other potential diagnosesand
identify the key features of SS. If a patient presents
to an ophthalmologist with typical ocular symp-
toms and signs, a rheumatology consultation
should be pursued early on in the diagnostic pro-
cess [7]. Ophthalmological evaluation of dry eye
symptoms is an important step to distinguish
between evaporative dry eye (EDE) and ADDE, the
latter being associated with SS. ADDE is primarily
related to decreased lacrimal secretion and should
raise suspicionofSS.However, it isnotuncommon
for SS patients to display characteristics of both
ADDE and EDE [39]. Relevant ophthalmology
findings should be communicated with the
rheumatologist to aid in diagnosis.
In a large, prospective study of individuals
presenting to optometry and ophthalmology
centers in the US with clinically significant
ADDE [3], 11.6% of patients were diagnosed
with SS according to AECG 2002 revised criteria
[35]. Compared to patients who did not have SS,
the SS patients had significantly worse symp-
toms, conjunctival and corneal staining, and
Schirmer’s test results [3]. These findings sug-
gest that all patients with clinically significant
ADDE should be assessed for SS.
Dental care professionals should be vigilant
for dry mouth symptoms or signs of dry mouth
complications in their patients. In the absence
of clear pathology, based on clinical evidence or
patient questioning, any suspicion of SS should
prompt referral or consultation with a
rheumatologist.
Tests Commonly Used in the Assessment
of SS
The tests for making a diagnosis of SS are pri-
marily focused on dry eye etiology, the salivary
glands, and biomarkers. Tear function tests
[40, 41] are used to distinguish between ADDE
and EDE, as mentioned above. Schirmer’s test
and tear meniscus assessment (tear lake) may
help identify ADDE and distinguish it from
EDE; the details of the differential diagnosis of
dry eye have been reviewed in greater detail
elsewhere [42, 43]. The tear function index (TFI)
and vital dye stains (Rose Bengal; lissamine
green) are also used. A recent analysis of data
from the Sjo¨gren’s Syndrome International
Registry [44] suggested that corneal staining
and conjunctival staining were associated with
an increased likelihood of a positive labial sali-
vary gland biopsy and should be part of the SS
workup in dry eye patients; conjunctival stain-
ing was also highly associated with positive
serology findings (anti-SS-A, anti-SS-B). The
5-item Dry Eye Questionnaire (DEQ-5) was val-
idated in 2010; it was found that scores [6
indicate dry eye, and scores [12 indicate the
need for further testing to rule out SS [45].
Lacrimal gland biopsy has been studied for
diagnostic value in SS [46], but is rarely per-
formed in clinical practice. This procedure is
much more invasive than minor salivary gland
biopsy and carries a risk of inflicting further
injury to an already compromised lacrimal
gland.
Minor Salivary Gland Biopsy
Although invasive, biopsy of minor salivary
glands has been traditionally considered the
gold standard for making the diagnosis of SS
[7, 47], and is one of the objective criteria
cited by the ACR [36]. While labial salivary
gland histopathologic findings offer a high
degree of specificity for SS [36], experience
suggests that biopsy findings identify SS at
more advanced stages of disease when gland
damage has already occurred. Salivary gland
biopsy is typically done by an oral care pro-
fessional. It is important that biopsy inter-
pretation be performed by a pathology
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professional experienced with SS histology to
avoid diagnostic errors. Salivary gland ultra-
sonography (SGUS) can aid in the differential
diagnosis of primary SS [48] and has been
reported to improve the diagnostic accuracy
of the ACR classification criteria for SS
[49–52]. However, there is a great deal of
heterogeneity among SGUS scoring systems,
and the procedure needs to be further stan-
dardized to increase its reproducibility
[51, 53]. Another noninvasive and potentially
useful test not mentioned in any SS diagnostic
guidelines is acoustic radiation force impulse
(ARFI) imaging of the parotid and sub-
mandibular glands; its diagnostic sensitivity is
81%, and its specificity is 67% [54].
Biomarkers
Traditional biomarkers for SS include anti-
SS-A/Ro, anti-SS-B/La, ANA, and RF. Current
ACR criteria include positivity for at least one
or more of these biomarkers (or meeting
threshold ANA titer) as partial fulfillment of
SS diagnosis (Table 1) [36]. Of these tradi-
tional biomarkers, the newest joint ACR/
EULAR guidelines include only anti-SS-A/Ro,
but positivity for this biomarker is a major
contributor to diagnosis [38]. It has been
shown that autoantibodies may be present
before the onset of SS symptoms. In a small
study, 29/64 (66%) of patients with primary
SS had detectable autoantibodies as early as
18 years before symptom onset [55], and in a
larger study, 81% of sera collected up to
20 years before diagnosis were positive for
one or more traditional biomarkers [56]. The
presence of SS-A/Ro antibodies is associated
with a higher risk of extraglandular manifes-
tations such as anemia, cryoglobulinemia,
leukopenia, vasculitis, and thrombocytope-
nia; such patients require close monitoring
[10].
Novel Biomarkers for SS
Although the traditional biomarkers are diag-
nostically important, they are not always posi-
tive in SS patients, especially in early cases, nor
are they specific for SS. In fact, the traditional
markers anti-SS-A and anti-SS-B have been
found to be positive in only about half of SS
patients who presented to ophthalmology
clinics with dry eye [10]. This has prompted
research into other potential biomarkers.
Based on experiments in mouse models of
SS, it has been hypothesized that SS begins as
an organ-specific disease initially involving
the salivary and lacrimal glands, and that
early diagnosis of SS might be facilitated by
looking for antibodies to proteins specific to
these glands [57]. In fact, three early
biomarkers of SS have been identified that are
specific to proteins selectively originating
from the salivary and lacrimal glands, unlike
SS-A and SS-B autoantibodies which are found
in virtually every cell. These new biomarkers
are auto-antibodies to salivary protein-1
(SP-1), parotid secretory protein (PSP), and
carbonic anhydrase VI (CA-6) [58, 59]. An
emerging hypothesis regarding SS pathogene-
sis includes a major role of the innate
immune system [60]. These proteins (SP-1,
PSP, CA-6) have various physiologic activities,
including roles in the adherence and/or
clearance of various infections [59]. High
levels of mRNA for SP-1 have been found in
the lacrimal and submandibular glands of
mice, but its human homologue is currently
unknown. It was identified as a product of one
of the genes upregulated in the thymus by the
autoimmune regulator gene (AIRE) to prevent
development of T lymphocytes. PSP is a pro-
tein that is involved in the binding and
clearance of infectious agents, while CA-6 is
an enzyme that has been found to be involved
in the buffering of saliva, and it is found in
the cytoplasm and secretory granules of serous
acinar cells in the submandibular and parotid
glands [58].
A small number of studies to date have
evaluated the diagnostic significance and
chronological pattern of biomarker positivity
in SS. In a study using an interleukin 14alpha
transgenic (IL14aTG) mouse model which
develops many features of SS, Shen et al.
found that only about 25% of the IL14aTG
mice developed antibodies to SS-A or SS-B
[58]. Further investigations of the timing of
antibody appearance found that antibodies to
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SP-1 and CA-6 occurred earlier and at much
higher prevalence overall compared with
anti-SS-A or anti-AA-B antibodies. The same
investigators also tested sera from 13 patients
having SS for at least 5 years and found 69%
of them positive for antibodies to SP-1 or
CA-6. While 62% of the patients tested posi-
tive for the traditional biomarkers (anti-SS-A
or anti-SS-B), 38% of the patients tested neg-
ative for these antibodies [58]. Finally, the
investigators tested the sera from 29 patients
with idiopathic xerostomia and xeroph-
thalmia of less than 2 years’ duration, all of
whom met at least three diagnostic criteria for
SS. Within this group of patients with appar-
ent early SS, 76% demonstrated antibodies to
SP-1 or CA-6, while only 31% had antibodies
to SS-A or SS-B [58].
In another study involving 123 patients
diagnosed with SS, sera from 19% of the
patients tested positive for anti-SP-1 anti-
bodies despite testing negative for anti-SS-A
and anti-SS-B, suggesting that diagnosis
might have been missed by relying on tradi-
tional biomarker testing alone [61]. In a study
using sera from the sicca cohort, anti-SS-A
and anti-SS-B positivity identified patients
with more severe (or longer duration disease)
SS than anti-SP-1, anti-CA-6, and anti-PSP
[59]. A recent study in 37 patients with
long-standing SS and high anti-SS-A/Ro titer
found anti-CA-6 antibodies in 38% of
patients but low positivity for antibodies to
SP-1 or PSP [62]. These findings suggest that
the novel biomarkers, particularly anti-SP-1
and anti-PSP, are less likely to be detected in
advanced primary SS. The same authors also
reported that antibodies to SP-1, CA-6, and
PSP were more sensitive and specific than
anti-SS-A/Ro in patients with SS in conjunc-
tion with other autoimmune diseases, which
might have been an indication of earlier stage
SS in these patients [62].
In an analysis of 6300 dry eye patients,
1544 cases were positive for SS biomarkers. A
majority (72.6%) of the positive cases were
positive only for the early biomarkers, while
27.3% were positive for both the early and
late biomarkers [63]. In a population of
patients with idiopathic dry eye, 60%
expressed positivity for antibodies to SP-1,
CA-6, or PSP, and 30% were positive for tra-
ditional SS antibodies [64]. While a number of
these patients also reported dry mouth, none
had been diagnosed with SS. These studies
suggest that the new biomarkers may identify
those patients who are early in the develop-
ment of SS, though it remains to be seen if
these early biomarkers are predictive of even-
tual development of systemic SS symptoms.
The Sjo¨ Test
The Sjo¨ test (Bausch & Lomb, Bridgewater, NJ,
USA) is a commercially available diagnostic
panel designed for the early detection of SS
using blood samples. This test assesses the
presence of four traditional Sjo¨gren’s
biomarkers (anti-SS-A/Ro, anti-SS-B/La, ANA,
and RF) along with three novel, proprietary
early biomarkers, antibodies to SP-1, PSP, and
CA-6 (Table 3). Unlike tests such as ultra-
sound imaging, the Sjo¨ test has the advantage
of not being operator-dependent and, thus,
potentially more objective. It was initially
available only as an in-office finger stick test
which presented certain barriers such as dif-
ficulties with the blood draw procedure and
insufficient sample volumes. Currently, how-
ever, the Sjo¨ panel can be ordered as a labo-
ratory test, with fewer barriers other than
laboratory accessibility and cost/reimburse-
ment issues.
The combination of novel and traditional
biomarkers in the Sjo¨ diagnostic panel provides
a greater sensitivity and specificity than tradi-
tional biomarker testing alone, and may facili-
tate early identification of patients with SS,
including patients who test negative for tradi-
tional biomarkers. A recent analysis showed
that the cumulative sensitivity of the complete
Sjo¨ panel was 91.8% (245/267); the sensitivity
for anti-SS-A/SS-B alone was 74.9% (200/267),
while the sensitivity for the novel biomarker
antibodies alone was 49.8% (133/267). The
cumulative specificity for the complete Sjo¨
panel was 79.8% (151/189), and the cumulative
specificity for the novel biomarkers was 83.5%
(158/189) [65].
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A retrospective chart review collected data
on 48 consecutive patients (83% female; mean
age, 62 years; 83% White) with refractory dry
eye who were evaluated for possible SS using the
Sjo¨ diagnostic test [66]. Inclusion criteria
included cases of dry eye that had failed to
respond as expected to traditional therapy as
well as patients with concomitant dry eye and
dry mouth symptoms. Potentially eligible cases
were excluded only for lack of serological test
results. Seven of the 48 cases considered to be
eligible could not be evaluated because insuffi-
cient sera was collected. Of the remaining 41
cases, 11 (27%) tested positive for at least one SS
biomarker (Fig. 1). Among these 11 positive
cases, almost all (10/11; 91%) were positive for
the early biomarkers anti-SP-1, anti-PSP-1, or
anti-CA-6, while substantially fewer cases were
positive for ANA (18%), RF (18%), and anti-SS-A
and/or anti-SS-B (27%) [66]. The investigators
acknowledged that biomarker positivity was
just one step in a longer diagnostic process, but
the testing provided evidence to trigger further
work-up and additional evaluation by other
specialists including rheumatologists.
Several case reports have highlighted the
real-world utility of using the Sjo¨ diagnostic
panel to make the diagnosis of SS [67–69]. A
series of three previously published cases
involved patients who had a history of dry eye
and tested negative for the classic biomarkers
(anti-SS-A/SS-B), but tested positive for the early
biomarkers using the Sjo¨ diagnostic test [67].
The first case was a 50-year-old male patient
who first developed dry eye symptoms follow-
ing laser-assisted in situ keratomileusis surgery
OD. This patient sought help from multiple
ophthalmologists and was treated with an array
of topical dry eye therapies, oral doxycycline,
and insertion of punctal plugs. Upon presenta-
tion to the author’s clinic, the patient was
found to have meibomian gland dysfunction
and was noted to have additional complaints
of dry mouth and joint pain. These findings
prompted referral to a rheumatologist for
auto-immune workup, the results of which
were negative except for human leukocyte
antigen B27 positivity. The patient was given
an initial diagnosis of fibromyalgia. The
patient continued to experience severe symp-
toms including pain and photophobia, and
was eventually tested using the Sjo¨ diagnostic
panel when it became available. While he
tested negative for the classic markers of ANA,
RF, anti-SS-A, and anti-SS-B, results showed
positivity for antibodies to SP-1, PSP, and
CA-6. The patient was presumed to have early
SS and referred back to a rheumatologist for
further care. He was treated with oral
hydroxychloroquine therapy and later treated




Anti-SS-A/Ro, anti-SS-B/La Not speciﬁc for SS; occurs in other autoimmune disorders,
particularly SLE
Antinuclear antibody (ANA) Titer C1:40 present in about two-thirds of SS patients [35]
Rheumatoid factor (RF) Found in many rheumatic conditions but is not unique to SS
Novel biomarkers/autoantibodies [54]
Salivary protein-1 (SP-1) Greatest sensitivity and speciﬁcity for early SS
Carbonic anhydrase VI (CA-6) Expressed very early in the course of SS; observed rarely in RA or
normal controls
Parotid secretory protein (PSP) Expressed early in SS; observed rarely in RA or normal controls
RA rheumatoid arthritis, SLE systemic lupus erythematosus, SS Sjo¨gren’s syndrome
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with compounded dapsone eye drops. While
he continued to experience significant symp-
toms, he was eventually able to discontinue
the hydroxychloroquine and has done well
with long-term dapsone drops. The other two
cases followed similar patterns, including
long-term complaints of dry eye symptoms
with unsatisfactory responses to a range of
interventions including artificial tears, topical
cyclosporine, topical corticosteroids, punctal
plugs, azithromycin ophthalmic solution, and
oral omega 3 supplements. These patients had
no apparent joint pain or other non-ocular
complaints at the time. Both were tested using
the Sjo¨ diagnostic panel and were found pos-
itive for antibodies to SP-1, PSP, and CA-6.
Both patients were negative for anti-SS-A and
anti-SS-B; one showed positivity for ANA and
RF, while the other was negative for these
traditional biomarkers. Both of these patients
were also referred to a rheumatologist.
Several additional published cases have
reported the diagnostic value of SP-1 antibody
testing in patients who met the clinical criteria
for SS but in whom diagnosis was delayed
because of negative test findings for traditional
biomarkers [68, 69]. Such cases highlight the
reality that not all individuals with SS will test
positive for traditional biomarkers and addi-
tional testing for additional autoantibodies may
be warranted, despite the absence of these
biomarkers from current diagnostic guidelines.
It would be of interest to evaluate the diagnostic
correlation between novel biomarker testing
and the current gold standard of salivary gland
biopsy; however, such data are not presently
available.
Investigational Biomarkers
A number of additional biomarkers are being
investigated for potential usefulness in SS
diagnosis. They include anti-kallikrein anti-
body, anti-LK11 antibody [70], specific anti-
bodies against carbamilate proteins [71],
antibodies against TRIM38 proteins [72],
lymphotoxin a, and tear cathepsin S. Further
work is needed to determine the utility of
these biomarkers.
CONCLUSION
Sjogren’s syndrome typically presents with very
non-specific symptoms, creating diagnostic
challenges and delays. Timely diagnosis of SS
requires appropriate clinical suspicion and
diagnostic follow-up in patients with the classic
symptoms of the disease, including dry mouth
and dry eye, particularly ADDE. Dry eye com-
plaints, especially if combined with dry mouth
symptoms, should trigger investigative steps to
rule out SS.
Fig. 1 Distribution of Sjo¨gren’s syndrome biomarkers among 11 cases of refractory dry eye showing positivity for at least 1
biomarker with the Sjo¨ diagnostic test; adapted with permission from Matossian et al. [66]. ANA antinuclear antibodies,
CA-6 carbonic anhydrase VI, PSP-1 parotid secretory protein 1, SP-1 salivary protein-1, RF rheumatoid factor
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Collaborative efforts involving ophthalmol-
ogists, rheumatologists, dentists, and other
specialists can facilitate accurate and early
identification of SS using a variety of comple-
mentary diagnostic tools. Diagnostic guidelines
continue to be refined, yet are not universally
reliable. The Sjo¨ diagnostic test is a simple,
non-invasive, operator-independent tool that
can help make the diagnosis of SS by identifying
both traditional and novel early-expressed SS
biomarkers. This simple laboratory test can
trigger additional definitive workup and
improve the chances for early diagnosis and
effective intervention.
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